Ikena Oncology Company Insiders

Ikena Oncology Management Team Effectiveness

The company has return on total asset (ROA) of (0.2206) % which means that it has lost $0.2206 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3709) %, meaning that it created substantial loss on money invested by shareholders. Ikena Oncology's management efficiency ratios could be used to measure how well Ikena Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Ikena Oncology's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.7 M, whereas Other Current Assets are forecasted to decline to about 2.9 M. As of November 22, 2024, Common Stock Shares Outstanding is expected to decline to about 40.8 M. In addition to that, Net Loss is expected to decline to about (65 M)

Ikena Oncology Workforce Comparison

Ikena Oncology Insider Trading

Ikena Oncology Notable Stakeholders

The success or failure of an entity such as Ikena Oncology often depends on how effective the management is. Ikena Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ikena management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ikena management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Ikena Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ikena Oncology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ikena Oncology's management manipulating its earnings.

When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.